PREMIUM SEARCH Search by job title, geography and build a list of executive contacts
JP Morgan downgraded Alcon (ACL
) to neutral from overweight.
Analyst Michael Weinstein believes prospects remain relatively upbeat for the vision care pharmaceuticals company. Still, after a strong 2002 he sees greater upside potential with comparable companies that offer higher top-line growth potential and more meaningful leverage through the operating income line.
Weinstein notes his MedTech strategy for 2003 favors higher beta cardiovascular names over orthopedic companies and more traditional medical suppliers. As a result, his Alcon downgrade is in light of a recent upgrade of cardiovascular company St. Jude Medical, which he named his Top Pick for 2003.
Any advice, analysis, or recommendations contained in articles labeled "Insight from Standard & Poor's" reflect the views of Standard & Poor's, which operates separately from and independently of BusinessWeek Online. It is possible that BWOL may from time to time publish information that is not consistent with advice, analysis, or recommendations that are published by Standard & Poor's. Standard & Poor's and BusinessWeek Online are each units of The McGraw-Hill Companies, Inc.
Get BusinessWeek directly on your desktop with our RSS feeds.
Add BusinessWeek news to your Web site with our headline feed.
Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.
To subscribe online to BusinessWeek magazine, please click here.
Copyright 2003, Bloomberg L.P.
Printer-Friendly Version
